Table 2 Diagnostic performances of SARC-F-3 and MSRA-5
Sensitivity | Specificity | Positive Likelihood Ratio | Negative Likelihood Ratio | |
|---|---|---|---|---|
SARC-F-3 | ||||
Low muscle mass | ||||
EWGSOP1 | 8.6% (1.8–23.1) | 82.1% (72.9–89.2) | 0.48 (0.15–1.54) | 1.11 (0.97–1.28) |
EWGSOP2 | 27.8% (9.7–53.5) | 86.6% (78.9–92.3) | 2.07 (0.86–5.01) | 0.8 (0.62–1.12) |
Low muscle strength | ||||
EWGSOP1 | 17.2% (10.2–26.4) | 89.2% (74.6–96.9) | 1.59 (0.57–4.45) | 0.93 (0.80–1.07) |
EWGSOP2 | 15.7% (8.1–26.4) | 85.0% (73.4–92.9) | 1.05 (0.47–2.36) | 0.99 (0.86–1.15) |
Sarcopenia | ||||
EWGSOP1 | 9.7% (2.0–25.8) | 82.8% (73.9–89.7) | 0.56 (0.18–1.80) | 1.09 (0.94–1.26) |
EWGSOP2 | 16.7% (0.4–64.1) | 84.7% (77.1–90.5) | 1.09 (0.17–6.82) | 0.98 (0.68–1.42) |
MSRA-5 | ||||
Low muscle mass | ||||
EWGSOP1 | 2.9% (0.1–14.9) | 89.5% (81.5–94.8) | 0.24 (0.04–2.04) | 1.09 (0.99–1.19) |
EWGSOP2 | 22.2% (6.4–47.6) | 93.8% (87.6–97.5) | 3.56 (1.16–10.93) | 0.83 (0.65–1.07) |
Low muscle strength | ||||
EWGSOP1 | 7.5% (3.1–14.9) | 89.2% (74.6–96.9) | 0.70 (0.22–2.24) | 1.04 (0.91–1.18) |
EWGSOP2 | 2.9% (0.4–9.9) | 85% (73.4–92.9) | 0.19 (0.04–0.85) | 1.14 (1.02–1.28) |
Sarcopenia | ||||
EWGSOP1 | 3.2% (0.1–16.7) | 89.9% (82.2–95.1) | 0.32 (0.04–2.40) | 1.08 (0.98–1.18) 1.10 (1.04–1.16) |
EWGSOP2 | 0% (0.0–45.9) | 91.1% (84.7–95.5) | 0 | |